| ACADIA Pharmaceuticals: Advancing On Several Fronts |
ACADIA Pharmaceuticals posted better-than-expected Q1 results earlier this month. The company has a rock solid balance sheet and advancing a couple of key drug candidates within its pipeline. An updated analysis around ACADIA Pharmaceuticals follows in the paragraphs below. |
seekingalpha.com |
2025-05-13 16:01:31 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) |
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago. |
zacks.com |
2025-05-09 23:30:34 |
Czytaj oryginał (ang.) |
| Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth |
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales. |
zacks.com |
2025-05-08 15:40:36 |
Czytaj oryginał (ang.) |
| ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript |
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Al Kildani - SVP of IR & Corporate Communications Catherine Owen Adams - CEO Tom Garner - COO Elizabeth Thompson - EVP and Head of R&D Mark Schneyer - EVP and CFO Conference Call Participants Ritu Baral - TD Cowen Tessa Romero - JPMorgan Ash Verma - UBS Elaine Kim - Canter Basma Radwan - Leerink Partners David Huang - Deutsche Bank Tazeen Ahmad - Bank of America Yatin Suneja - Guggenheim Joel Beatty - Baird Sumant Kulkarni - Canaccord Genuity Malcolm Hoffman - BMO Capital Markets Operator Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Conference Call. My name is Lauren Cannon, and I'll be your coordinator for today. |
seekingalpha.com |
2025-05-08 00:10:23 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates |
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago. |
zacks.com |
2025-05-07 22:41:20 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2025. “2025 is off to a strong start for Acadia, achieving total revenue of $244.3 million in the first quarter,” said Catherine Owen Adams, Chief Executive Officer. “DAYBUE has achieved meaningful patient growth for the first time since the second quarter of 2024, serving more patients this quarter than in any prior quarter, and NUPLAZID continues t. |
businesswire.com |
2025-05-07 20:05:00 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 3:40 p.m. Pacific Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuti. |
businesswire.com |
2025-05-05 20:05:00 |
Czytaj oryginał (ang.) |
| 5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates |
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings. |
zacks.com |
2025-05-05 14:15:41 |
Czytaj oryginał (ang.) |
| Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline |
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-30 15:07:18 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025 |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 7, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia's website, Acadia.com under the investors section and will be archived there until August 6, 2025. The conference call may also be ac. |
businesswire.com |
2025-04-23 20:05:00 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 172,637 shares of common stock and 64,791 restricted stock units (“RSUs”) to twenty-two new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees'. |
businesswire.com |
2025-04-11 20:05:00 |
Czytaj oryginał (ang.) |
| Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar? |
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-04-10 14:35:57 |
Czytaj oryginał (ang.) |
| Acadian upgraded to Equal Weight from Underweight at Morgan Stanley |
Morgan Stanley upgraded Acadian Asset Management to Equal Weight from Underweight with a price target of $26, up from $25. The company's skew to overseas assets will insulate its possible downside to earnings relative to peers, the analyst tells investors in a research note. Further, the firm sees potential increased appeal of Acadian's non-U.S. equity strategies to the extent investors increase allocations to rest of world. |
https://thefly.com |
2025-04-07 09:17:03 |
Czytaj oryginał (ang.) |
| Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? |
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2025-03-28 14:36:26 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 71,981 shares of common stock and 42,159 restricted stock units (“RSUs”) to thirteen new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' em. |
businesswire.com |
2025-03-14 18:05:00 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fireside Chat: Monday, March 17, 2025 at 11:00 a.m. Eastern Time Stifel 2025 Virtual CNS Forum Fireside Chat: Wednesday, March 19, 2025 at 12:30 p.m. Eastern Time 24th Annual Needham Virtual Healthcare Conference Fireside Chat: Monday, April 7, 2025 at 10:15 a.m. Eastern Time Live webcasts of each fireside chat wi. |
businesswire.com |
2025-03-13 18:05:00 |
Czytaj oryginał (ang.) |
| Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE had a similar safety profile in children two to four years of age as that observed in individuals with Rett syndrome five years of age an. |
businesswire.com |
2025-03-05 11:05:00 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised) |
Acadia Pharmaceuticals (ACAD) came out with fourth-quarter earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.28 per share a year ago. |
zacks.com |
2025-03-05 09:40:26 |
Czytaj oryginał (ang.) |
| Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised) |
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales. |
zacks.com |
2025-03-04 07:10:39 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals Ends FY2024 On Solid Footing |
ACADIA Pharmaceuticals reported its fourth quarter results this week and provided initial guidance for FY2025, highlighting key financial metrics and future projections. The company continues to see solid growth from its two products on the market and has also build up a large amount of net cash on its balance sheet. ACADIA Pharmaceuticals is also advancing several key assets within its developmental pipeline. |
seekingalpha.com |
2025-03-02 07:19:48 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 11:10 a.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceu. |
businesswire.com |
2025-02-27 18:05:00 |
Czytaj oryginał (ang.) |
| Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth |
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales. |
zacks.com |
2025-02-27 13:50:18 |
Czytaj oryginał (ang.) |
| ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript |
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q4 2024 Results Conference Call February 26, 2025 4:30 PM ET Company Participants Al Kildani - SVP of Investor Relations & Corporate Communications Catherine Owen Adams - CEO Tom Garner - COO Elizabeth Thompson - EVP, Head of R&D Mark Schneyer - EVP, CFO Conference Call Participants Ami Fadia - Needham & Company Tessa Romero - JPMorgan Joel Beatty - Baird Tazeen Ahmad - Bank of America Securities Gregory Renza - RBC Capital Markets Charles Duncan - Cantor Sumant Kulkarni - Canaccord Genuity LLC Operator Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Conference Call. My name is Shannon, and I will be your coordinator for today. |
seekingalpha.com |
2025-02-26 22:13:02 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates |
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.28 per share a year ago. |
zacks.com |
2025-02-26 20:25:33 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. “We closed 2024 on a strong note with each of our brands achieving record revenues in the fourth quarter and well-positioned for continued growth in 2025,” said Catherine Owen Adams, Chief Executive Officer. “To support this growth in 2025 we will continue investing in consumer activation to drive market share expansion for NU. |
businesswire.com |
2025-02-26 18:05:00 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on February 6, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 171,065 shares of common stock and 55,170 restricted stock units (“RSUs”) to eighteen new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees. |
businesswire.com |
2025-02-14 18:05:00 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock? |
Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately. |
zacks.com |
2025-02-13 11:30:32 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on February 26, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia's website, Acadia.com under the investors section and will be archived there until May 26, 2025. The. |
businesswire.com |
2025-02-12 18:05:00 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on January 13, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 23,782 shares of common stock and 13,928 restricted stock units (“RSUs”) to twelve new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' e. |
businesswire.com |
2025-01-17 18:05:00 |
Czytaj oryginał (ang.) |
| ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised) |
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026. |
zacks.com |
2025-01-16 12:30:47 |
Czytaj oryginał (ang.) |
| ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals |
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026. |
zacks.com |
2025-01-15 15:45:21 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. “2025 is shaping up to be an exciting year as we build on the success of our two growing brands, NUPLAZID and DAYBUE, which together are proj. |
businesswire.com |
2025-01-14 11:05:00 |
Czytaj oryginał (ang.) |
| Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-31 13:01:20 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the Company in a session scheduled on Tuesday, January 14, 2025, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time. A live webcast of Acadia's presentation will be accessible on the company's website, Acadia.com, under the investors section and an archi. |
businesswire.com |
2024-12-19 18:05:00 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 4, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 38,568 shares of common stock and 22,264 restricted stock units (“RSUs”) to thirteen new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees'. |
businesswire.com |
2024-12-16 18:05:00 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses. As described at the time the agreement to sell was announced on November 5, 2024, Acadia is required to pay Neuren Pharmaceuticals Limited one-third of the net proceeds, pursuant to a license agreement between the companies. Acadia plans to invest proceeds from the sale of the PRV to. |
businesswire.com |
2024-12-11 18:05:00 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial strategy and operations, driving the Company's plans for sustained growth and expansion of its product portfolio and pipeline across U.S. and international markets. Mr. Garner will report to Catherine Owen Adams, Acadia's CEO, and serve on the executive leadership team. “Tom is. |
businesswire.com |
2024-12-09 11:00:00 |
Czytaj oryginał (ang.) |
| Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-03 12:55:49 |
Czytaj oryginał (ang.) |
| Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET |
NUPLAZID and DAYBUE are each delivering double-digit percentage net product sales growth. Company is on track to reach more than $1 billion in annualized net product sales in 2025. Next phase of growth could come from two late-stage assets known as ACP-101 for hyperphagia of PWS and ACP-204 for Alzheimer's Disease Psychosis. |
seekingalpha.com |
2024-11-27 17:18:51 |
Czytaj oryginał (ang.) |
| ACAD Signs License Deal With Saniona for Rights to Neurology Drug |
Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications. |
zacks.com |
2024-11-27 13:11:08 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711 |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. The first indication the Company plans to pursue is development of SAN711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the bo. |
businesswire.com |
2024-11-26 18:05:00 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Citi's 2024 Global Healthcare Conference Fireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL 7th Annual Evercore HealthCONx Conference Fireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eastern Time in Coral Gables, FL Live webcasts of each fireside chat will be accessible on the company's website, Acadia.com, und. |
businesswire.com |
2024-11-21 18:05:00 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on November 8, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 70,571 shares of common stock and 40,731 restricted stock units (“RSUs”) to twenty-three new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employ. |
businesswire.com |
2024-11-15 18:05:00 |
Czytaj oryginał (ang.) |
| Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-11-12 12:56:22 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals: Proving The Naysayers Wrong |
Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some 20% last week following Q3 results. The company beat both top and bottom-line expectations and also posted updated FY2024 guidance. Acadia Pharmaceuticals is becoming profitable, has a pristine balance sheet, and is seeing solid growth. |
seekingalpha.com |
2024-11-11 12:50:46 |
Czytaj oryginał (ang.) |
| Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth |
ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth. |
zacks.com |
2024-11-07 13:05:22 |
Czytaj oryginał (ang.) |
| ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript |
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript |
seekingalpha.com |
2024-11-06 22:09:14 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates |
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to loss of $0.40 per share a year ago. |
zacks.com |
2024-11-06 20:21:22 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction. Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of DAYBUE™ (trofinetide) for the treatment of Rett syndrome. DAYBUE was initially licensed by Acadia from Neuren Pharmaceutical. |
businesswire.com |
2024-11-05 18:05:00 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release |
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-30 13:07:04 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024 |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on November 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will be available on Acadia's website, Acadia.com under the investors section and will be archived. |
businesswire.com |
2024-10-17 22:41:00 |
Czytaj oryginał (ang.) |
| Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome |
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older under the Priority Review process. The Notice of Compliance authorization of DAYBUE makes it the first and only drug approved in Canada for the treatment of Rett syndrome. Rett syndrome is a rare, complex, neurodevelopmental disorder affe. |
businesswire.com |
2024-10-16 20:07:00 |
Czytaj oryginał (ang.) |